EGFR Amplification clinical trials at UCSD

1 research study open to eligible people

BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-driven Advanced Solid Tumors
open to eligible people ages 18 years and up
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
La Jolla, California and other locations

Last updated: November 6, 2024